Immucor agrees to acquire Hologic's Lifecodes transplant diagnostics business in a deal worth up to $95 million, marking the 1st publicly reported acquisition by Immucor since former Medtronic CEO William Hawkins took the corner office.
In-vitro diagnostics maker Immucor  (NSDQ:BLUD ) signed a definitive agreement to acquire the Lifecodes transplant diagnostics business of Hologic  (NSDQ:HOLX ) in a deal worth up to $95 million.
Immucor paid $85 million in cash, with another $10 million to be paid out for certain financial milestones, according to a press release.
The Lifecodes business is a "worldwide leader in transplantation diagnostics," part of a $400 million global market that Immucor says is growing fast. Hologic acquired Lifecodes' technology in August 2012 when it acquired  molecular diagnostics giant Gen-Probe  (NSDQ:GPRO ) for $4 billion.